

STATEMENT OF PURPOSE

RS22993C1

In the past few years Idaho has experienced an increase in the number of "designer" drugs seized through law enforcement actions. Deaths due to these drugs are occurring around the country and in Idaho. Federal legislation has scheduled nine "2C" compounds, three "NBOMe" compounds, and two "substituted amphetamine" drugs. There are many more of these dangerous substances that have not been federally scheduled. Federally scheduled drugs become scheduled in Idaho statute thirty days after they are federally scheduled if the Idaho Board of Pharmacy does not object. The Board of Pharmacy then formalizes these drugs being added to the Idaho schedules during the next legislative session. The Idaho approach of scheduling classes of synthetic and designer drugs has been very successful. Because these drugs can be changed very quickly to avoid statutory restrictions, the class approach avoids the need for special legislative sessions each time a new drug in a class emerges as a threat to public safety. This legislation specifically controls all currently known and any yet to be developed drugs within the "2C" class, the "25 NBOMe" class, and the "substituted amphetamine" class. Specific consideration was given to exclude drugs in other schedules and therapeutic drugs.

FISCAL NOTE

Exact fiscal impact is unknown at this time. However, at the current time the actual cost of analysis per case is \$185-200 per sample. Based on these numbers and handling 72-180 cases per year, the anticipated cost for lab analysis will be between \$14,400.00 and \$36,000.00 which includes purchase of analytical laboratory standards, processing of cases at the laboratory, and court testimony related to analytical laboratory findings.

Contact:

Senator Todd M. Lakey
(208) 332-1328